"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Descriptor ID |
D000276
|
MeSH Number(s) |
D27.505.696.477.067
|
Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 5 | 2 | 7 |
1996 | 3 | 2 | 5 |
1997 | 2 | 3 | 5 |
1998 | 2 | 5 | 7 |
1999 | 2 | 5 | 7 |
2000 | 8 | 3 | 11 |
2001 | 7 | 4 | 11 |
2002 | 6 | 1 | 7 |
2003 | 8 | 12 | 20 |
2004 | 7 | 5 | 12 |
2005 | 6 | 9 | 15 |
2006 | 10 | 8 | 18 |
2007 | 8 | 4 | 12 |
2008 | 6 | 6 | 12 |
2009 | 10 | 8 | 18 |
2010 | 10 | 5 | 15 |
2011 | 11 | 4 | 15 |
2012 | 3 | 8 | 11 |
2013 | 7 | 6 | 13 |
2014 | 4 | 6 | 10 |
2015 | 7 | 11 | 18 |
2016 | 6 | 11 | 17 |
2017 | 5 | 4 | 9 |
2018 | 6 | 12 | 18 |
2019 | 4 | 5 | 9 |
2020 | 5 | 9 | 14 |
2021 | 8 | 14 | 22 |
2022 | 2 | 17 | 19 |
2023 | 0 | 20 | 20 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial. Nat Commun. 2024 Mar 22; 15(1):2570.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13; 12(3).
-
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 Feb 14; 229(2):327-340.
-
Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.
-
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Nov 02; 389(18):1672-1684.
-
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov; 29(11):2835-2843.
-
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447.
-
Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Oncotarget. 2023 09 15; 14:811-818.
-
Identification of a Self-Assembling Small-Molecule Cancer Vaccine Adjuvant with an Improved Toxicity Profile. J Med Chem. 2023 09 28; 66(18):13266-13279.
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.